| Investigator (year of publication) | Chuansumrit A27 (1995) |
Wu R13 (2011) |
Tang L14 (2013) |
Verma SP25 (2016) |
Gouider E28 (2017) |
Chozie NA26 (2019) |
Lambert C29 (2020) | Wu R (2021) |
|---|---|---|---|---|---|---|---|---|
| Country | Thailand | China | China | India | Tunisia | Indonesia | Ivory Coast | China |
| Type of study | Observational | Observational | Observational | Randomized controlled trials | Observational | Randomized controlled trials | Prospective | Observational |
| Period of study enrollment, y | 1992 | 2007‐2009 | 2008‐2009 | 2013 | ND | 2016‐2018 | 2018‐2020 | 2016‐2017 |
| Duration of prophylaxis | 1 y‐ | 12 wks | 6‐12 wks | 11.5 mo | 5 y | 12.8 mo | 17 mo | 1 y |
| Type of prophylaxis | Tertiary |
Secondary/ Tertiary |
Secondary/ Tertiary |
Secondary | Secondary | Secondary/Tertiary | Primary/Secondary | Secondary |
| Number of evaluable cases | 6 | 34 | 66 | 11 | 51 | 25 | 25 | 33 |
| Hemophilia A | 6 | 28 | 66 | 11 | 42 | 25 | 21 | 33 |
| Hemophilia B | 6 | 9 | 4 | |||||
| Regimen | FVIII: 8‐10 IU/kg twice a week |
FVIII: 10 IU/kg twice a week FIX: 20 IU/kg once weekly |
FVIII: 10 IU/kg twice a week | FVIIII: 10 IU/kg twice a week |
FVIII: 20‐30 IU/kg once weekly to 15 IU/kg twice a week with escalation based on bleeding: FIX: 25–35 IU/kg once weekly with escalation based on bleeding: |
FVIII: 10 IU/kg twice a week | Fc‐rVIII: 20 IU/kg once weekly; Fc‐rIX: 20 IU/kg once every 10 days | FVIII: 10‐15 IU/kg twice a week with escalation based on bleeding |
| Factor consumption IU/kg/y | 832‐1040 |
FVIII =1040 FIX =1040 |
960 | 1050.1 | 1612 | 1010 (median) | ND | |
| Annualized index joint bleeds (AJBR) during the preprophylaxis period (eg, on demand) | ND | 5.8 (mean) | ||||||
| Observed | 9.9 (mean) | 7.0 (median) | 10.3 | |||||
| Projected | 39.6 (mean) | 28.8 (mean) | 4.0 (median) | |||||
| Age at start of prophylaxis, y | 12 (median) | 7.5 (median) | 8.6 (mean) | 4.3 (mean) | 5.3 (median) | 11.8 (mean) | 5.6 (mean) | 4.8 (median) |
| Annualized index joint bleeds (AJBR) in the period of low‐dose prophylaxis | ND | 1.7 (mean) | ||||||
| Observed | 0.96 (mean) | 0.5 (median) | 5.6 | 1.9 (mean) | 3.0 (median) | |||
| Projected | 7.37 (mean) | 6.0 (mean) |
Data in this table are taken directly from the published manuscripts, with extrapolation where appropriate (ie, project annualized index joint bleeds).
Abbreviation: ND, No data provided.